Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease

Neurobiology of Aging

Volumn 30, Issue 8, 2009, Pages 1205-1216

  He, Jue ^a,c   Luo, Huanmin ^b   Yan, Bin ^c   Yu, Yingxin ^c   Wang, Haitao ^c   Wei, Zelan ^c   Zhang, Yanbo ^c   Xu, Haiyun ^d   Tempier, Adrien ^c   Li, Xiaokun ^a   Li, Xin Min ^a,c,e  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Amyloid; Secretase; Alzheimer's disease; APP PS1 double transgenic mouse model; Memory; Plaque; Quetiapine

Indexed keywords

3 NITROTYROSINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CELL PROTEIN; PRESENILIN 1; PROTEIN BCL 2; PROTEIN C99; QUETIAPINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRAIN CORTEX; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HIPPOCAMPUS; MAZE TEST; MEMORY DISORDER; MOUSE; NEUROPATHOLOGY; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIPSYCHOTIC AGENTS; ANXIETY; BRAIN; DIBENZOTHIAZEPINES; DISEASE MODELS, ANIMAL; FEMALE; MALE; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; PRESENILIN-1; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CELL SURFACE; SENILE PLAQUES; TYROSINE;

EID: 67349203223     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.11.001     Document Type: Article

References (52)

1. Apelt J., Bigl M., Wunderlich P., and Schliebs R. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int. J. Dev. Neurosci. 22 (2004) 475-484
2. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., and Diamond D.M. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891 (2001) 42-53
3. Asai M., Hattori C., Iwata N., Saido T.C., Sasagawa N., Szabo B., Hashimoto Y., Maruyama K., Tanuma S., Kiso Y., and Ishiura S. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J. Neurochem. 96 (2006) 533-540
4. Bai O., Wei Z., Lu W., Bowen R., Keegan D., and Li X.M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 69 (2002) 278-283
5. Bai O., Zhang H., and Li X.M. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res. 1010 (2004) 81-86
6. Caballero J., Hitchcock M., Scharre D., Beversdorf D., and Nahata M.C. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: A retrospective study. Clin. Ther. 28 (2006) 1695-1700
7. Cantillon M., De La Puente A.M., and Palmer B.W. Psychosis in Alzheimer's disease. Semin. Clin. Neuropsychiatry 3 (1998) 34-40
8. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., Younkin S.G., and Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2 (1999) 271-276
9. Clementi M.E., Pezzotti M., Orsini F., Sampaolese B., Mezzogori D., Grassi C., Giardina B., and Misiti F. Alzheimer's amyloid beta-peptide (1-42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem. Biophys. Res. Commun. 342 (2006) 206-213
10. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
11. Fukumoto H., Rosene D.L., Moss M.B., Raju S., Hyman B.T., and Irizarry M.C. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol. 164 (2004) 719-725
12. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., and Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
13. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.V., Hope C.E., Hatcher J.M., DiCarlo G., Gottschall W.P., Morgan D., and Arendash G.W. Correlation between cognitive deficits and Abeta deposits in transgenic APP + PS1 mice. Neurobiol. Aging 22 (2001) 377-385
14. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
15. He J., Xu H., Yang Y., Zhang X., and Li X.M. Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of bcl-2 decrease in rats. Brain Res. 1018 (2004) 186-192
16. He J., Xu H., Yang Y., Zhang X., and Li X.M. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav. Brain Res. 160 (2005) 178-187
17. He J., Xu H., Yang Y., Rajakumar D., Li X., and Li X.M. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav. Brain Res. 168 (2006) 236-242
18. He J., Yang Y., Yu Y., Li X., and Li X.M. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav. Brain Res. 172 (2006) 39-45
19. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., and Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4 (1998) 97-100
20. Howard S., Bottino C., Brooke S., Cheng E., Giffard R.G., and Sapolsky R. Neuroprotective effects of bcl-2 overexpression in hippocampal cultures: interactions with pathways of oxidative damage. J. Neurochem. 83 (2002) 914-923
21. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
22. Juncos J.L., Roberts V.J., Evatt M.L., Jewart R.D., Wood C.D., Potter L.S., Jou H.C., and Yeung P.P. Quetiapine improves psychotic symptoms and cognition in parkinson's disease. Mov. Disord. 19 (2004) 29-35
23. Kane D.J., Sarafian T.A., Anton R., Hahn H., Gralla E.B., Valentine J.S., Ord T., and Bredesen D.E. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262 (1993) 1274-1277
24. Kluck R.M., Bossy-Wetzel E., Green D.R., and Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
25. Lazarov O., Robinson J., Tang Y.P., Hairston I.S., Korade-Mirnics Z., Lee V.M., Hersh L.B., Sapolsky R.M., Mirnics K., and Sisodia S.S. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120 (2005) 701-713
26. Li R., Lindholm K., Yang L.B., Yue X., Citron M., Yan R., Beach T., Sue L., Sabbagh M., Cai H., Wong P., Price D., and Shen Y. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 3632-3637
27. Luo C., Xu H., and Li X.M. Post-stress changes in BDNF and bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res. 1025 (2004) 194-202
28. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., and Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158 (2001) 1345-1354
29. 2 and kainic acid: implications for Alzheimer's disease. J. Neurochem. 96 (2006) 1322-1335
30. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11 (1984) 47-60
31. Puolivali J., Wang J., Heikkinen T., Heikkila M., Tapiola T., van Groen T., and Tanila H. Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol. Dis. 9 (2002) 339-347
32. Purdon S.E., Malla A., Labelle A., and Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 26 (2001) 137-149
33. Qing H., Xu H., Wei Z., Gibson K., and Li X.M. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur. J. Neurosci. 17 (2003) 1563-1570
34. Scharre D.W., and Chang S.I. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis. Assoc. Disord. 16 (2002) 128-130
35. Schneider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., Lebowitz B.D., Lyketsos C.G., Ryan J.M., Stroup T.S., Sultzer D.L., Weintraub D., Lieberman J.A., and CATIE-AD study group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N. Engl. J. Med. 355 (2006) 1525-1538
36. Shimizu S., Narita M., and Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399 (1999) 483-487
37. Storey E., and Cappai R. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol. Appl. Neurobiol. 25 (1999) 81-97
38. Street J.S., Clark W.S., Gannon K.S., Cummings J.L., Bymaster F.P., Tamura R.N., Mitan S.J., Kadam D.L., Sanger T.M., Feldman P.D., Tollefson G.D., Breier A., and The HGEU study group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen. Psychiatry 57 (2000) 968-976
39. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., and Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 13287-13292
40. Suh Y.H., and Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54 (2002) 469-525
41. Tong Y., Zhou W., Fung V., Christensen M.A., Qing H., Sun X., and Song W. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J. Neural. Transm. 112 (2005) 455-469
42. Van Gassen G., and Annaert W. Amyloid, presenilins, and Alzheimer's disease. Neuroscientist 9 (2003) 117-126
43. Velligan D.I., Newcomer J., Pultz J., Csernansky J., Hoff A.L., Mahurin R., and Miller A.L. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr. Res. 53 (2002) 239-248
44. Velligan D.I., Prihoda T.J., Sui D., Ritch J.L., Maples N., and Miller A.L. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J. Clin. Psychiatry 64 (2003) 524-531
45. Wang H., Xu H., Dyck L.E., and Li X.M. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 81 (2005) 572-580
46. Wei Z., Bai O., Richardson J.S., Mousseau D.D., and Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 73 (2003) 364-368
47. Wei Z., Mousseau D.D., Richardson J.S., Dyck L.E., and Li X.M. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid (25-35) by modulating bax and bcl-X(l/s) expression and localization. J. Neurosci. Res. 74 (2003) 942-947
48. Wilquet V., and De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr. Opin. Neurobiol. 14 (2004) 582-588
49. Wragg R.E., and Jeste D.V. Overview of depression and psychosis in Alzheimer's disease. Am. J. Psychiatry 146 (1989) 577-587
50. Yamada K., Noda Y., Hasegawa T., Komori Y., Nikai T., Sugihara H., and Nabeshima T. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J. Pharmacol. Exp. Ther. 276 (1996) 460-466
51. Yang L.B., Lindholm K., Yan R., Citron M., Xia W., Yang X.L., Beach T., Sue L., Wong P., Price D., Li R., and Shen Y. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9 (2003) 3-4
52. 2-induced apoptosis in human neuronal cells. Biochem. Biophys. Res. Commun. 235 (1997) 845-848